Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis

American Journal of Gastroenterology

Volumn 99, Issue 10, 2004, Pages 1953-1958

  Lin, Han Chieh ^a   Yang, Ying Ying ^b   Hou, Ming Chih ^b   Huang, Yi Tsau ^b   Lee, Fa Yauh ^b   Lee, Shou Dong ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ISOSORBIDE 5 NITRATE; PROPRANOLOL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEART INDEX; HEART RATE; HEMODYNAMIC MONITORING; HEPATIC VEIN; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; OUTCOMES RESEARCH; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRESSURE GRADIENT; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS HEPATITIS;

ANTIHYPERTENSIVE AGENTS; CARBAZOLES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION, PORTAL; ISOSORBIDE DINITRATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPANOLAMINES; PROPRANOLOL; VASODILATOR AGENTS;

EID: 7044237420     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40179.x     Document Type: Article

References (41)

1. Lebrec D, Poynard T, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981;305:1371-4.
2. Lebrec D, Hillon P, Muñoz C, et al. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 1982;2:523-7.
3. De Franchis R. Portal Hypertension III. Proceedings of the third Baveno international consensus workshop of definitions, methodology and therapeutic strategies. Blackwell Science Ltd. London, 2001.
4. Feu F, Garcia-Pagán JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
5. García-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6.
6. Vorobioff J, Picabea E, Villavicencio R, et al. Acute & chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987;7:648-53.
7. García-Pagán JC, Navasa M, Bosch J, et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990;11:230-8.
8. Merkle C, Sacerdoti D, Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology 1997;26:34-9.
9. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-45.
10. Villanueva C, Miñana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55.
11. Zweiten PA. Pharmacodynamic profile of carvedilol. Cardiology 1993;2(suppl3):19-23.
12. Forrest EH, Bouchier IAD, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996;25:909-15.
13. Stanley AJ, Therapondos G, Helmy A, et al. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999;30:479-84.
14. Bañares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha 1-adrenergic activity has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999;30:79-83.
15. Bañares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367-73.
16. Pugh RNH, Murray-Lyon M, Dawson JL, et al. Transection of oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
17. Lin HC, Tai YT, Lee FY, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992;103:229-34.
18. Lin HC, Tsai YT, Lee FY, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol 1989;9:326-30.
19. Perelló A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999;30:1393-7.
20. Forrester JS, Ganz W, Diamond G, et al. Thermodilution cardiac output determination with a single flow-directed catheter. Am Heart J 1972;83:306-11.
21. Bosch J. Effect of pharmacological agents on portal hypertension: A hemodynamic appraisal. Clin Gastroenterol 1985;14:169-84.
22. Bosch J, Kravetz D, Navasa M. Effects of vasopressin on variceal pressure and azygos blood flow. In: Lebrec D, Blei AT, eds. Vasopressin analogs and portal hypertension. Paris: John Libbey Eurotext, 1987;95-104.
23. García-Pagán JC, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. Ann Intern Med 1991;114:869-73.
24. McCormick PA, Patch D, Greenslade L, et al. Clinical vs. haemodynamic response to drugs in portal hypertension. J Hepatol 1998;28:1015-19.
25. Navasa M, Chesta J, Bosch J, et al. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989;96:1110-18.
26. Jones AL, Bengash IH, Walker J, et al. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose of isosorbide-5-mononitrate in patients with cirrhosis. Gut 1995;36:104-9.
27. Tsai YT, Lee FY, Lin HC, et al. Lack of effects of isosorbide-5- mononitrate on hepatic hemodynamics in HbsAg-positive cirrhosis. Hepatology 1989;10:283-7.
28. Reynaert H, Thompson MG, Thomas T, et al. Hepatic stellate cells: Role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-81.
29. Albillos A, García-Pagán JC, Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998;115:116-23.
30. Floras JS, Legault L, Morali GA, et al. Increased sympathetic outflow in cirrhosis and ascites: Direct evidence from intraneural recording. Ann Intern Med 1991;114:373-80.
31. Grossman HJ, Grossman VL, Bhathal PS. Enhanced vasoconstrictor response of the isolated perfused liver preparations from normal and cirrhotic rats. J Gastroenterol Hepatol 1992;7:283-7.
32. Marteau P, Ballet F, Chazouilléres O, et al. Effect of vasodilators on hepatic microcirculation in cirrhosis: A study in the isolated perfused rat liver. Hepatology 1989;9:820-3.
33. Albillos A, Lledó JL, Bañares R, et al. Hemodynamic effects of α-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994;20:611-17.
34. Bosch J, Mastai R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984;4:1200-5.
35. Mastai R, Bosch J, Bruix J, et al. β-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology 1989;10:269-72.
36. Merkel C, Sacerdoti D, Bologensi M, et al. Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. Eur J Gastroenterol Hepatol 1999;11:1221-5.
37. Blei AT, Gottstein J. Isosorbide dinitrate in experimental portal hypertension: A study of factors that modulate the hemodynamic response. Hepatology 1986;6:107-11.
38. Merkel C, Finicci G, Zuin R, et al. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. J Hepatol 1987;4:174-80.
39. Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001;21:161-74.
40. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW et al. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat liver. Hepatology 2002;36:381-5.
41. 1- blocking properties of carvedilol during acute and chronic administration. J Cardiovasc Res 1992;19(suppl1):S18-22.